ITMCTR2000002885尚未招募1 期
Evaluation of efficacy and safety of Qiangzhu-qinggan formula as an adjunctive therapy in adult patients with severe influenza
onghua Hospital Shanghai University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 65（—）
- 性别
- All
入选标准
- •1. Diagnosis of influenza A and/or B by a positive Rapid Influenza Diagnostic Test (RIDT) or reverse transcriptase-polymerase chain reaction (RT-PCR). Positive results from local tests are acceptable if conducted within the 24 hours prior to screening. A patient with a negative RIDT may be enrolled if influenza is suspected based on local surveillance data or if the patient reports contact with a known case of influenza within the prior 7 days and all other inclusion criteria are met.
- •2. Granting of written informed consent.
- •3. Male or female aged 18 to 65 years at the time of signing Informed Consent Form.
- •4. Ability to comply with the study protocol, in the investigators judgment.
- •5. Participants who require hospitalization for severe influenza or acquire influenza during hospitalization, the severity of which requires an extension of hospitalization.
- •6. Participants will require at least one of the following objective criteria of severe influenza:
- •(1) duration with axillary temperature over 39 degrees Celsius >= 3 days, accompanied by severe cough, sputum, blood sputum, or chest pain;
- •(2) rapid respiratory rate(>= 30 times per minute), difficulty breathing and cyanosis of lips;
- •(3) arterial oxygen saturation (SaO2)/ pulse oxygen saturation (SPO2) <= 94% in room air condition;
- •(4) Requires ventilation or supplemental oxygen to support respiration;
- •(5) with only one complication related to influenza (e.g., pneumonia, central nervous system involvement, myositis, rhabdomyolysis, acute exacerbation of chronic kidney disease, asthma or chronic obstructive pulmonary disease (COPD), severe dehydration, myocarditis, pericarditis, exacerbation of ischemic heart disease).
- •7. The time interval between the onset of symptoms and randomization is within 96 hours. The onset of symptoms is defined as either: Time of the first increase in body temperature (>=38?); Time when the patient experiences at least one general or respiratory symptom.
- •8. Conforming to the standard of TCM syndrome differentiation.
排除标准
- •1. Aged <18 years or >65 years.
- •2. Participants hospitalized for exclusively social reasons (e.g., lack of caregivers at home).
- •3. Participants expected to be discharged within 48 hours, according to the investigator's judgement.
- •4. Participants weighing < 40 kg.
- •5. Participants who have received more than 48 hours of antiviral treatment for the current influenza infection prior to screening.
- •6. Participants with known severe renal impairment or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis.
- •7. Participants with any of the following laboratory abnormalities detected within 24 hours prior to or during screening (according to local laboratory reference ranges:
- •(1)Alanine Transaminase (ALT) or Aspartate Transaminase (AST) level > 5 times the upper limit of normal (ULN).
- •(2)ALT or AST > 3 times the ULN and total bilirubin level > 2 times the ULN.
- •8. Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study.
- •9. With mental changes or convulsions (e.g., slow response, drowsiness and restlessness).
- •10. With severe gastrointestinal symptoms (e.g., severe nausea, vomiting, diarrhea and even dehydration).
- •11. With one of the following critical illnesses: respiratory failure, acute necrotic encephalopathy, septic shock, multiple organ dysfunction, or other serious clinical conditions requiring intensive care.
- •12. With tuberculosis, measles, AIDS or other infectious diseases.
- •13. Women who are pregnant (including a positive pregnancy test at enrollment), breastfeeding, or within 2 weeks post-partum.
- •14. Known history of allergy or severe intolerance of oseltamivir and herbal medicines, as determined by the investigator.
- •15. Currently or have been involved in another anti-influenza treatment trial in the last 28 days.
- •16. Patients who have been treated with oral Chinese medicine within 4 weeks.
- •17. Patients who, in the opinion of the investigator, would be unlikely to comply with required study visits, self-assessments, and interventions.
研究者
相似试验
已完成
不适用
Evaluation of efficacy and safety of the Qing Dai in patients with ulcerative colitis: A muticenter, double-blind, randomized controlled trial.ulcerative colitisJPRN-UMIN000019103The Jikei University Kashiwa Hospital68
招募中
不适用
Evaluation of the clinical efficacy of Qinghuatanshi Decoction in the treatment of Plasma cell mastitis during perioperative periodPlasma cell mastitisITMCTR2100005055Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine
招募中
4 期
???????????????????ITMCTR2200005917Gansu Province second People's Hospital
尚未招募
1 期
Evaluation of curative effect and safety of Qinji Liangxue mixture on hemorrhagic internal hemorrhoids of excess heat type based on ultrasonic elastographyInternal hemorrhoidsITMCTR2000004002Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
尚未招募
1 期
Presentation on the efficacy and safety of Kuanxiong aerosol in improving exercise tolerance in patients with coronary heart disease and angina pectorisITMCTR2000003106Guangdong Provincial Hospital of Chinese Medicine